Accurate Education, Pain Medications – Buprenorphine

Buprenorphine for Pain

It is recommended to first read the following sections to become familiarized with some of the terms and concepts related here:

 

Neurobiology of Pain

Neuropathic Pain

Opioids

Neurobiology of Opioids

Opioid Induced Hyperalgesia

 

Also see:

Buprenorphine Treatment – Emergency and Surgery Pain Management

Buprenorphine in Pregnancy & Breast Feeding

Naloxone (Opioid Blocker)

Methadone for Pain

Levorphanol

Oxymorphone (Opana)

Tapentadol

 

 See also: Buprenorphine for Opioid Substance Use Disorder (SUD)

 

Definitions and Terms Related to Pain

 

Key to Links:

Grey text – handout

Red text – another page on this website

Blue text – Journal publication

hormones

‘‘Freedom from pain should be a basic human right, limited only by our knowledge to achieve it”

– Melzack R.

Opioids – Buprenorphine for Pain

 

Buprenorphine for Pain – A Brief Overview

Buprenorphine is an opioid medication commonly used for treating pain and, because of it’s special characteristics, it is also offers significant potential advantages for pain management over other opioids. While buprenorphine is also commonly used for treating opiate addiction, many people have the mistaken belief that it is used only for addiction which is not the case at all. Buprenorphine also appears to have the advantage of being less likely to develop tolerance to it’s pain benefits compared to many other opioids.  Because buprenorphine is different, even those patients with high tolerance that require high doses of opioids such as oxycodone to control their pain usually respond well to buprenorphine for pain control.

 

Buprenorphine has an extensive set of unique properties that include:

(1) High potency: more potent than morphine, hydrocodone and oxycodone;

(2) Long half-life and slow dissociation from the mu-receptor, providing advantages over other opioids;

(3) Safety advantages over other opioids, including a  “ceiling response” to respiratory depressive effects, a benefit that makes buprenorphine potentially the safest opioid with respect to unintentional overdose;

(4) Buprenorphine binds tightly to the mu-receptor (the opioid receptor where all commonly  prescribed opioids act to reduce pain);

(5) Buprenorpine offers greater analgesic benefits than some of the other commomly prescribed opioids for certain types of pain including neuropathic pain, deep bone pain and certain cancer-related pains.

(6) Buprenorphine reduces depression, probably by blocking the kappa-receptor (another opioid receptor), a property that makes buprenorphine also effective as a mood elevator;

(7) Buprenorphine displays a limited degree of analgesic tolerance that likely stabilizes over time and is often effective for patients who have developed analgesic tolerance to other opioids;

(8) Buprenorpine does not reduce testosterone levels in men or women as can occur with other opioids;

(9) Buprenorpine does not appear to reduce the immune response, a finding of still undetermined significanc that appears to occur with some other opioids;

(10) Buprenorpine can be used more safely with those with pancreatitis;

(11) Buprenorphine has less affect on the sphincter of Oddi than many other opioids;

(12) Withdrawal symptoms with buprenorphine are less severe than many other opioids;

(13) Buprenorphine is one of the safest opioids for use in renal failure and dialysis;

(14) Buprenorphine is better tolerated in the elderly than many other opioids;

(15) Buprenorphine may be given with other opioids and may improve  safety in the combination

 

 

Buprenorphine for Pain – the Details

(1) Buprenorphine is a very potent opioid for pain – it is estimated to be approximated 40-135 times as potent, milligram per milligram, when compared to oral morphine, depending on the way it is taken (IV vs sublingual or transbuccal vs transdermal). This is why the dosing of buprenorphine is provided in low doses, starting with fractions of a milligram for patients who have not built significant tolerance to the use of opioids.

 

(2) Buprenorphine has a long half-life, meaning that it stays in the body for a long time before it is broken down (metabolized) and/or eliminated, so its effects can last a long time. The analgesic effects of buprenorphine can control pain up to 8-12 hours after a single dose.  When a person is physically dependent on opioids, buprenorphine can suppress withdrawal symptoms for up to 48-72 hours after the last dose. Buprenorphine slowly dissociates/detaches from the mu-receptor, a property that also makes the withdrawal symptoms from buprenorphine milder than other opioids.

 

(3) Buprenorphine also has safety advantages compared with other opioids. All opioids share the property of respiratory depression, in which at higher doses an opioid will suppress the brain’s drive to breathe, resulting in an overdose that can be fatal. A unique beneficial  property of buprenorphine is it’s “ceiling effect” with respect to respiratory depression, where there is a limit to the extent in which buprenorphine will suppress the drive to breathe. This property makes it much less likely to result in an accidental overdose, a benefit that may also apply to those with other risks for respiratory depression or reduced oxygenation such as those with sleep apnea, COPD, congestive heart failure or history of stroke. That being said, one is still susceptible to overdose from buprenorphine especially if taken with alcohol, benzodiazepines or other sedatives such as Soma or barbiturates like Fioricet or Fiorinal.

 

Buprenorphine is likely safer in the elderly and those with kidney or liver impairment. Only 10-30% of buprenorphine is eliminated via the liver and kidney, the rest is eliminated in the stool. No dosing adjustments are required for those on dialysis (it is not dialyzed) or those who have kidney or liver disease.

 

(4) Buprenorphine has a strong affinity to the mu-receptor, meaning that it binds tightly to the receptor. Because its binding affinity is stronger than many other currently prescribed opioids, it may displace another opioid already attached to that receptor. When a person who has been on opioids long enough to establish physical dependency, such a displacement of other opioids can precipitate a withdrawal reaction if buprenorphine is given at a high enough dose to displace a significant percentage of another opioid present. This is referred to as a “precipitated opioid withdrawal response” and can complicate the process of rotating from taking another opioid to buprenorphine. For this reason it is important that you follow the guidelines established by your prescribing physician to avoid this.

(See: Rotating to Buprenorphine from Another Opioid).

 

This property of strong affinity of buprenorphine has led to the erroneous belief that taking another opioid for pain while taking buprenorphine will be ineffective. This is not true. Depending on the dose of  buprenorphine one is taking, and the percentage of mu-opioid receptors occupied by the buprenorphine, the additional opioid will react with unoccupied receptors for an additive effect. Other variables contributing to the ultimate response of the second opioid include the dose, potency and affinity of the second opioid. Morphine, oxycodone and hydromorphone have all been demonstrated to be effective when added to buprenorpine for pain.

 

(5) Buprenorphine is more effective for certain types of pain than some other opioids. It is particularly effective in controlling neuropathic (nerve) pain in cancer and non-cancer conditions to a greater extent than many other opioids. Common examples of neuropathic pain include diabetic peripheral neuropathy, shingles, post-radiation pain and sciatica. There is also evidence that buprenorphine may reverse hyperalgesia, a hypersensitivity to pain that may occur with chronic opioid use, a benefit possibly related to buprenorphine blocking kappa-opioid receptors.  Buprenorphine also reduces allodynia, the condition in which stimuli such as soft touch or light pressure are inappropriatedly perceived as painful. Both hyperalgesia and allodynia are pain conditions noted to occur in chronic pain patients, especially fibromyalgia patients.

(See Neuropathic Pain)

 

Buprenorphine is also noted to block central sensitization by multiple mechanisms, thus reducing not only the centrally-induced increased pain associated with long-term chronic pain but also the other sensory sensitivities that may evolve with various chronic pain syndromes.

See: Central Sensitization

 

A study published in 2011 evaluated buprenorphine as compared to fentanyl in the management of deep, bone pain, the type associated with bone trauma and metastatic cancer. This type of pain is often difficult to manage with conventional opioids such as fentanyl. The study revealed buprenorphine to be effective in this type of pain, where fentanyl was not, due to unique characteristics of buprenorphine and its metabolism.

 

(6) Recent studies indicate that buprenorphine is beneficial for depression, likely by blocking the kappa-receptor (another opioid receptor). 

 

(7) Buprenorphine has multiple mechanisms for reducing pain that often makes it  especially effective for patients who have developed analgesic tolerance to other opioids. Aside from its action on the mu-opioid receptors in common with other opioids, it appears to also be activate another receptor in the spinal cord that reduces pain (the ORL1 receptor). Buprenorphine also may have another mechanism for reducing pain by direct action in the brain which is not blocked by naloxone, thus it is a mechanism independent of the mu-opioid receptor. Buprenorphine, like other opioids,  does display analgesic tolerance but it appears to be limited and it likely stabilizes over time.

 

(8) As appears to be the case with other opioids, buprenorpine does not reduce testosterone levels in men or women. Testosterone is a hormone that plays a role in pain physiology that is not yet well understood. However, it appears to be associated with a greater tolerance for pain and may be a contributing factor to the higher prevalence of chronic pain in women. Some pain conditions such as cluster headaches may also be associated with low levels of testosterone. 

 

(9) Buprenorpine does not appear to impair the immune system,  as has been found with some other opioids. Opioids binding to mu-opioid receptors in the brain can activate the descending pathways of the hypothalamo-pituitary-adrenal (HPA) axis, increasing the production of immunosuppressive glucocorticoids (steroids like cortisol) whch have been found to reduce the immune response to stress and may possibly contribute to an increased risk for infection. However, the clinical significance of this reduced immune response is as yet unclear. While not all opioids have demonstrated this effect (tramadol does not, morphine and fentanyl do), buprenorphine may have an advantage  over certain other opioids in conditions of reduced immune function.

 

(10) Buprenorpine can be used more safely with those with acute or chronic pancreatitis. Most opioids are known to cause spasm of the sphincter of Oddi, a muscular valve that controls the flow of digestive juices (bile and pancreatic juice) through ducts from the liver and pancreas into the first part of the small intestine (duodenum). Sphincter of Oddi spasm the back-up of juices into the gall bladder and pancreas and causes severe abdominal pain, especially in those with pancreatitis. Buprenorphine does not cause spasm of the sphincter of Oddi..

  

For those interested in learning more about buprenorphine and how it works, based on current research, please see end of document and reference articles below.

 

Prescribing Information for Safe Use of Buprenorphine

 

Buprenorphine with other opioids

Buprenorphine has a special characteristic compared with other opioids: it has a very strong binding affinity to the receptors in the nervous system that provide pain control. This means that it may displace other opioids in a patient’s system and this displacement may trigger withdrawal symptoms dependent on a person’s level of physical dependence to their opioids. For this reason it is important that you discuss with your physician how to make the transition from another opioid to buprenorphine before doing so. This strong binding characteristic of buprenorphine also means that when a patient is taking buprenorphine for pain, the addition of other opioids may be less likely to provide significant additional pain benefit. Again, there are a number of variables that come into play here including the dose of buprenorpine one is taking and which additional opioid. However, at lower doses such as those associated with Belbuca (a buccal strip) and Butrans patches, it has been clearly demonstrated that the addition of other commonly prescribed opioids will add analgesic benefit without impairment by the buprenorphine.

 

This does not mean, however, that one cannot overdose when adding other opioids when taking buprenorphine. In fact, one can. So it is advised to not take any other opioids while taking buprenorphine for pain unless guided by a physician with special knowledge regarding buprenorphine management. Such circumstances may arise under emergency conditions that are accompanied by severe pain not adequately controlled with buprenorphine. In the event this happens, be certain to notify your emergency physician that you are taking buprenorphine so that he can make appropriate decisions to effectively manage your pain.

See also: Naloxone

 

Different forms and different brands

Buprenorphine is available as a transdermal skin patch or as a pill or film strip designed to dissolve under the tongue or against the side of the cheek. Buprenorphine is available as a stand-alone medication or in combination with naloxone, a non-therapeutic secondary component added only as an abuse deterrent. Due to the popularity of opioid abuse, most opioids coming to market now are accompanied by some form of abuse deterrent and the addition of naloxone, an opioid blocker, is a popular form. The presence of naloxone offers no benefit for pain management but, if the formulation (tablet or film) is snorted or injected in an attempt to abuse the medication, the naloxone will trigger an immediate withdrawal syndrome meant to discourage abuse.

 

Butrans is a transdermal patch form of buprenorphine, designed to be worn for one week then replaced. It is an excellent and convenient means of treating mild to moderate chronic pain. Butrans is FDA approved for pain only, not addiction. Butrans contains only buprenorphine and comes in five dosage strengths ranging from 5 μg/hr to 20 μg/hr in patches designed to be replaced every 7 days.

 

Belbuca is a buprenorphine film that is applied to the cheek inside the mouth (buccal area). It contains only buprenorphine and comes in seven dosage strengths ranging from 75 μg to 900 μg, to be dosed every 12 hours.  Belbuca provides higher doses than Butrans patches but lower doses than the combination buprenorphine/naloxone tablets and strips (Suboxone, Zubsolv and Bunivail). Belbuca is FDA approved for pain only, not addiction.

 

Suboxone is the most well-known form of buprenorphine in combination with naloxone because it is commonly used to manage opioid addiction as a safer alternative to the use of methadone, another opioid used for both pain and addiction. Suboxone, like the other brands of buprenorphine tablets or film strips, is FDA approved for addiction treatment and therefore it’s use for pain is considered “off-label.” However, as noted above, buprenorphine as a drug is FDA approved for pain and many medications are commonly used “off-label.” Suboxone is available as a tablet or a film strip in four buprenorphine strengths: 2mg, 4mg, 8mg and 12 mg and is generally dosed every 8-12 hours for pain control.

 

Subutex is buprenorphine only, in tablet form and like Suboxone it is available in four strengths: 2mg, 4mg, 8mg and 12 mg.  Subutex is generally dosed every 8-12 hours for pain control. It is used almost exclusively in pregnancy.

 

Zubsolv is buprenorphine in combination with naloxone. It is a film strip designed to dissolve under the tongue and comes in two buprenorphine strengths: 1.4mg (a comparable dose to the 2mg Suboxone dose) and 4.2mg (a comparable dose to the 8mg Suboxone dose). The difference in dosing is due to the different bioavailability associated with the different proprietary formulation. Due to the equivavent bioavaiable dose with Zubsolv. It ihas been shown that Zubsolv dissolves more quickly than Suboxone and there is less buprenorphine being swallowed where it contributes to risk for constipation.

 

Bunavail is buprenorphine in combination with naloxone. It is a film strip designed to adhere to the cheek, then dissolve. It comes in three buprenorphine strengths: 2.1 mg (a comparable dose to the 4 mg Suboxone dose), 4.2 mg (a comparable dose to the 8mg Suboxone dose) and 6.3 mg (a comparable dose to the 12mg Suboxone dose. The difference in dosing is due to the different bioavailability associated with the different proprietary formulation.

 

Advantages of Bunavail

 

Bunavail is designed differently from Suboxone and Zubsolv. Rather than the single layer design, it is a bilayered film that promotes unidirectional drug flow across the buccal mucosa (lining of the cheek), allowing for less buprenorphine dissolving into saliva and more of it going into the blood through the cheek. Consequently, because less buprenorphine is wasted into saliva and swallowed, a smaller dose strip can be used with equal amounts of buprenorphine entering the blood.

 

Thus, while an equal amount of buprenorphine enters the blood compared with the other formulations, less buprenorphine enters the stomach and intestines. When buprenorphine enters the stomach and intestine, it is absorbed and transported to the liver which metabolizes the buprenorphine into norbuprenorphine, its primary metabolite. In a recent 2016 study, it was determined that norbuprenorphine blood levels were 40% lower with Bunavail compared with the sublingual preparations.

 

Norbuprenorphine is bioactive like buprenorphine but with different characteristics. Because it is a full mu-opioid agonist unlike the partial mu-opioid agonist, buprenorphine, norbuprenorphine has greater activity related to the mu-opioid receptor resulting in greater constipation effect. For this reason, the higher norbuprenorphine levels associated with Suboxone and Zubsolv compared with Bunavail are associated with more likelihood of constipation.  Therefore, if one experiences constipation with Suboxone or Zubsolv, a trial of Bunavail is warranted.

 

Another advantage of the buccal adherence to the cheek is the relative immediacy one can proceed to speak without waiting for a tab or strip to dissolve under the tongue.

 

Disadvantage of Bunavail

 

Because blood levels of norbuprenorphine are lower at comparable blood levels of buprenorphine with Bunavail compared with Suboxone and Zubsolv, it is likely that Bunavail does not have as much analgesic benefit due to the analgesic contribution of norbuprenorphine. This conclusion is speculative, however, with no definitive studies comparing analgesic benefits between the three versions.

 

Each proprietary formulation tastes different, with each taste appealing more or less to the individual.

 

What is the most important information I should know about taking Buprenorphine?

  1. Buprenorphine can cause death from overdose, especially if you take them with alcohol or sedatives such as Xanax, Valium or Klonopin. Use Buprenorphine exactly the way your doctor tells you to with medicines used to treat depression or anxiety.
  2. Use Buprenorphine only for the condition for which it was prescribed.
  3. Buprenorphine can cause drug dependence. This means that you can get withdrawal symptoms if you stop using it too quickly. Buprenorphine is not for occasional (“as needed”) use.
  4. Getting off buprenorphine can be accomplished without serious difficulty. The reason it sometimes has the reputation of being difficult to taper off is that the tapering is not done correctly. Buprenorphine is a potent opioid that should be tapered slowly;  you should not simply stop taking it abruptly when you get down to a 1 or 2mg/day dose. Use of alternative buprenorphine formulations and tapering regimens can be engaged to make the final taper smooth and well tolerated. There is growing research to suggest that the use of gabapentin (Neurontin) may ease opioid withdrawal symptoms (See: Gabapentin). Additionally, the use of Synaptamine during the tapering process may make the tapering better tolerated.
  5. Prevent theft and misuse. Buprenorphine is a narcotic painkiller that can be a target for people who abuse prescription medicines or street drugs. Keep your buprenorphine locked in a safe place, to protect them from theft. Never give them to anyone else. Selling or giving away this medicine is against the law.
  6. In an emergency, have family members tell emergency room staff that you are being treated with buprenorphine, especially if being treated for a severely painful condition. Buprenorphine binds very tightly to the opioid receptors (see: Neurobiology of Opioids) that provide pain relief, more than most other opioids including hydrocodone, oxycodone and morphine. This means that in the event of an emergency that demands pain medicines for pain not controlled by currently prescribed buprenorphine, the emergency physician should use the best opioid for pain or the buprenophine may impair the effectiveness of the second opioid. There are multiple variables that will contribute to how effective a second opioid will be for the patient currently taking buprenorphine. This ineffectiveness may be misinterpreted as drug-seeking by a physician not well informed regarding treating pain in patients who take buprenorphine. Perhaps the best two opioids for emergency use for managing pain in this emergency circumstance, either orally or intravenously, are hydromorphone (Dilaudid) or fentanyl. These two opioids have greater affinity for the opioid receptor than buprenorphine and should be effective for pain. That being said, caution is advised to avoid unintentional overmedication/overdose and careful monitoring should be employed. Whenever possible, always contact Dr. Ehlenberger (24/7) should you need to go to the emergency room for any condition, but especially for a painful condition.

 

Who Should Not Take Buprenorphine?

Do not take buprenorphine if:

  1. your doctor did not prescribe buprenorphine for you.
  2. you are allergic to buprenorphine, or any of the inactive ingredients in the medicines. See the end of this leaflet for a complete list of ingredients.

 

Your doctor should know about all your medical conditions before deciding if buprenorphine is right for you or what dose is best. Tell your doctor about all of your medical problems, especially the ones listed below:

  1. trouble breathing or lung problems  
  2. head injury or brain problem
  3. liver or kidney problems
  4. gallbladder problems
  5. adrenal gland problems, such as Addison’s disease
  6. low thyroid (hypothyroidism
  7. enlarged prostate gland (men)
  8. problems urinating
  9. a curve in your spine that affects your breathing
  10. severe mental problems or hallucinations (seeing or hearing things that are not really there  
  11. alcoholism

 

Tell your doctor:

  1. if you are pregnant or plan to become pregnant. Buprenorphine may not be right for you. It is not known whether buprenorphine could harm your baby.
  2. if you are breast feeding, buprenorphine will pass through your milk and may harm your baby.
  3. Tell your doctor about all the medicines you take, including prescription and non­prescription medicines, vitamins, and herbal supplements. They may cause serious side effects when taken with buprenorphine. Sometimes, the doses of certain medicines and buprenorphine need to be reduced if used together.
  4. Do not take any other medicine, herbal, or over-the-counter medicine while using buprenorphine unless your doctor has told you it is okay.

 

How should I take Buprenorphine?

  1. Follow your doctor’s directions exactly. Your doctor may change your dose after seeing how the medicine affects you. Do not change your dose unless your doctor tells you to change it. Do not take buprenorphine more often than prescribed.
  2. Put the tablets or film under your tongue or against the cheek as directed and let them melt. This will take 2 to 10 minutes. Do not chew or swallow the tablets. The medicine will not work this way and you may get withdrawal symptoms.
  3. If your doctor tells you to take more than 1 tablet/film, you will be told to:
  4. take all tablet/films at the same time together under your tongue, or
  5. take 2 tablet/films, put them under your tongue. After they melt, put the next tablet/film under your tongue right away
  6. hold the tablet/film under your tongue until they melt completely. The medicine will not work if swallowed and you may get withdrawal symptoms.
  7. Do not change the way you are told to take your medicine or you may get too little or too much medicine.
  8. Do not inject (“shoot-up”) buprenorphine. Shooting-up is dangerous and you may get bad withdrawal symptoms.
  9. Buprenorphine can cause withdrawal symptoms if you take them too soon after using opiate drugs like morphine, oxycodone, hydrocodone or methadone.
  10. If you miss a dose of buprenorphine, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once unless your doctor tells you to.
  11. Before discontinuing buprenorphine, ask your doctor how to avoid withdrawal symptoms.
  12. If you take too much buprenorphine or overdose, call your local emergency room or poison control center ASAP.
  13. If you discontinue taking buprenorphine, flush the unused tablets or strip down the toilet.

 

What Should I Avoid While Taking Buprenorphine?

  1. Do not drive, operate heavy machinery, or perform other dangerous activities until you know how this medicine affects you.
  2. Do not drink alcohol or take tranquilizers or sedatives (medicines that help you sleep) while using buprenorphine. You can die when you use these products with buprenorphine..
  3. Do not take other medicines without talking to your doctor. Other medicines include prescription and non-prescription medicines, vitamins, and herbal supplements. Be especially careful about medicines that may make you sleepy.

 

Potential Drug Interactions

There may also be a potential for a buprenorphine interaction with other drugs and compounds that induce or inhibit the cytochrome P-450 3A4 system, the enzyme system in the liver that metabolizes buprenorphine. There are many agents in this category and they include erythromycin, zileuton, and grapefruit juice and starfruit (inhibitors of metabolism), as well as carbamazepine, phenobarbital, phenytoin, and rifampin (inducers that enhance metabolism). In a study of the effects of the selective serotonin reuptake inhibitors (SSRIs) fluoxetine (Prozac) and fluvoxamine (Luvox), were both shown to inhibit buprenorphine metabolism, suggesting they may increase blood levels of buprenorphine if started on someone already taking buprenorphine.

 

What are the Possible Side Effects of Buprenorphine?

Some of the common side effects of buprenorphine are headache, drowsiness, problems sleeping, nausea, sweating, stomach pain, and constipation.These are not all the possible side effects of buprenorphine, just some of the most common.

 

Call your doctor or get medical help right away if:

  1. You feel faint, dizzy, confused, or have any other unusual symptoms.
  2. Your breathing gets much slower than is normal for you. These can be signs of an overdose or serious problem.
  3. Buprenorphine can cause your blood pressure to drop, causing dizziness if you get up too fast from sitting or lying down.
  4. Buprenorphine can cause allergic reactions that can make it hard for you to breathe. Other symptoms of a bad allergic reaction include hives, swelling of your face, asthma (wheezing) or shock (loss of blood pressure and consciousness).

Call a doctor or get emergency help right away if you get any of these symptoms.

 

Buprenorphine may cause liver problems. Call your doctor right away if:

  1. Your skin or the white part of your eyes turns yellow (jaundice).
  2. Your urine turns dark.
  3. Your bowel movements (stools) turn light in color.
  4. You don’t feel like eating much food for several days or longer.
  5. You feel sick to your stomach (nausea).
  6. You have lower stomach pain.

 

Your doctor will do blood tests while you are taking buprenorphine to make sure your liver is okay.

 

Other considerations:

  1. You may get withdrawal symptoms when you start treatment with buprenorphine. To avoid this, be sure other opiates are out of your system before starting buprenorphine.
  2. Like with all opiates, you can develop dependence from taking buprenorphine, so you may get withdrawal symptoms when you stop taking buprenorphine. There is also a chance that you may abuse or get addicted to buprenorphine.

 

Genetic Testing

At Accurate Clinic we highly recommend genetic testing for our opioid patients. Through testing our patient’s DNA with a simple oral swab of saliva from the cheek, an individual’s ability to metabolize opioids and other medications by the liver can be evaluated. This information provides important insights as to how a patient may respond to various medications, including buprenorphine, and where side effects or drug interactions may be predicted, allowing for substantial safety benefits in prescribing.

 

Neurobiology of Buprenorphine – for those interested in understanding more…

As noted above, buprenorphine has characteristics that make it particularly effective in managing certain types of pain. This is because buprenorphine has different mechanisms of action that conventional opioids (see Neurobiology of Opioids).

 

References:

 

Buprenorphine – Patient Information

  1. Buprenorphine Transdermal Patch: MedlinePlus Drug Information
  2. Buprenorphine – for Pain, Informed Consent

 

Buprenorphine Overviews

  1. Buprenorphine – Considerations for Pain Management
  2. Sublingual Buprenorphine:Naloxone for Chronic Pain in At-Risk Patients – Development and Pilot Test of a Clinical Protocol
  3. Is Levorphanol a Better Option than Methadone – 2015
  4. Transdermal buprenorphine in clinical practice: a multicenter, noninterventional postmarketing study in the Czech Republic. – PubMed – NCBI
  5. clinical-update-on-the-pharmacology-efficacy-and-safety-of-transdermal-buprenorphine-pubmed-ncbi
  6. opioids-and-the-management-of-chronic-severe-pain-in-the-elderly-consensus-statement-of-an-international-expert-panel-with-focus-on-the-six-clinic-pubmed-ncbi
  7. buprenorphine-an-attractive-opioid-with-underutilized-potential-in-treatment-of-chronic-pain-2015
  8. twelve-reasons-for-considering-buprenorphine-as-a-frontline-analgesic-in-the-management-of-pain-pubmed-ncbi
  9. the-clinical-analgesic-efficacy-of-buprenorphine-pubmed-ncbi
  10. current-knowledge-of-buprenorphine-and-its-unique-pharmacological-profile-pubmed-ncbi
  11. equipotent-doses-of-transdermal-fentanyl-and-transdermal-buprenorphine-in-patients-with-cancer-and-noncancer-pain-results-of-a-retrospective-cohor-pubmed-ncbi
  12. transdermal-buprenorphine-in-cancer-pain-and-palliative-care-pubmed-ncbi
  13. safety-and-effectiveness-of-intravenous-morphine-for-episodic-breakthrough-pain-in-patients-receiving-transdermal-buprenorphine-pubmed-ncbi
  14. evaluation-of-the-tolerability-of-switching-patients-on-chronic-full-l-opioid-agonist-therapy-to-buccal-buprenorphine-2016
  15. buprenorphine-naloxone-therapy-in-pain-management-2014
  16. efficacy-and-tolerability-of-buccal-buprenorphine-in-opioid-experienced-patients-with-moderate-to-severe-chronic-low-back-pain-2016
  17. management-of-moderate-to-severe-chronic-low-back-pain-with-buprenorphine-buccal-film-using-novel-bioerodible-mucoadhesive-technology-2016
  18. the_clinical_analgesic_efficacy_of_buprenorphine
  19. effect-of-transdermal-opioids-in-experimentally-induced-superficial-deep-and-hyperalgesic-pain-2011
  20. a-clinical-trial-comparing-tapering-doses-of-buprenorphine-with-steady-doses-for-chronic-pain-and-co-existent-opioid-addiction-2010
  21. Twelve Reasons for Considering Buprenorphine as a Frontline Analgesicin the Management of Pain – 2012
  22. The switch from buprenorphine to tapentadol – is it worth? – 2016

 

BuprenorphineConstipation

  1. Opioid-induced constipation_ rationale for the role of norbuprenorphine in buprenorphine-treated individuals – 2016
  2. Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine – Norbuprenorphine Is a Potent Opioid Agonist – 2001

 

BuprenorphineDrug Interactions

  1. Drug Interactions of Clinical Importance among the Opioids, Methadone and Buprenorphine

 

Buprenorphine – Opioid Tolerance, Hyperalgesia and NMDA Antagonism

  1. Buprenorphine – a review of its role in neuropathic pain
  2. Buprenorphine for neuropathic pain–targeting hyperalgesia. – PubMed – NCBI
  3. Transdermal buprenorphine controls central neuropathic pain. – PubMed – NCBI
  4. Pharmacologic Treatments for Neuropathic Pain

Emphasis on Education

 

Accurate Clinic promotes patient education as the foundation of it’s medical care. In Dr. Ehlenberger’s integrative approach to patient care, including conventional and complementary and alternative medical (CAM) treatments, he may encourage or provide advice about the use of supplements. However, the specifics of choice of supplement, dosing and duration of treatment should be individualized through discussion with Dr. Ehlenberger. The following information and reference articles are presented to provide the reader with some of the latest research to facilitate evidence-based, informed decisions regarding the use of conventional as well as CAM treatments.

 

For medical-legal reasons, access to these links is limited to patients enrolled in an Accurate Clinic medical program.

 

Should you wish more information regarding any of the subjects listed – or not listed –  here, please contact Dr. Ehlenberger. He has literally thousands of published articles to share on hundreds of topics associated with pain management, weight loss, nutrition, addiction recovery and emergency medicine. It would take years for you to read them, as it did him.

 

For more information, please contact Accurate Clinic.

 

Supplements recommended by Dr. Ehlenberger may be purchased commercially online or at Accurate Clinic.

Please read about our statement regarding the sale of products recommended by Dr. Ehlenberger.

Accurate Supplement Prices